Pathios Therapeutics is a clinical-stage oncology and immunology drug discovery and development company based in Oxfordshire, United Kingdom, founded in 2017. The company develops small-molecule inhibitors of the pH-sensing G protein-coupled receptor GPR65 to counteract the immunosuppressive tumor microenvironment; its lead asset PTT-4256 is a… - View it on GitHub